WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016097213) MONOCLONAL ANTIBODY FOR THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF BRAIN TUMORS AND BRAIN LESIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/097213    International Application No.:    PCT/EP2015/080349
Publication Date: 23.06.2016 International Filing Date: 17.12.2015
IPC:
A61P 35/00 (2006.01), C07K 16/30 (2006.01), C07K 16/18 (2006.01), C07K 16/28 (2006.01), A61K 39/00 (2006.01)
Applicants: ALTHIA HEALTH, S.L [ES/ES]; C/ Velázquez, nº 16 - 3ºD 28001 Madrid (ES).
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) [ES/ES]; C/ Serrano, 117 Madrid 28006 (ES)
Inventors: SILVA GONZÁLEZ, Augusto; (ES).
GARCÍA SANZ, José Alberto; (ES)
Agent: PONS ARIÑO, Ángel; (ES)
Priority Data:
14382545.3 19.12.2014 EP
Title (EN) MONOCLONAL ANTIBODY FOR THE DIAGNOSIS, TREATMENT AND/OR PREVENTION OF BRAIN TUMORS AND BRAIN LESIONS
(FR) ANTICORPS MONOCLONAL POUR LE DIAGNOSTIC, LE TRAITEMENT ET/OU LA PRÉVENTION DE TUMEURS CÉRÉBRALES ET DE LÉSIONS CÉRÉBRALES
Abstract: front page image
(EN)The invention relates to the use of the monoclonal antibody NILO1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use of said monoclonal antibody, or immunologically active fragments thereof, as a medicament for the treatment and/or prevention of brain tumors and brain lesions. In a preferred embodiment of the invention, the monoclonal antibody NILO1, or its immunologically active fragments, are humanized.
(FR)L'invention concerne l'utilisation de l'anticorps monoclonal NILO1 pour le diagnostic, le traitement et/ou la prévention de tumeurs et de lésions cérébrales. L'invention concerne en particulier des méthodes pour le diagnostic de tumeurs cérébrales et de lésions cérébrales, consistant à détecter des cellules marquées avec ledit anticorps, ou avec des fragments immunologiquement actifs de celui-ci. L'invention concerne également l'utilisation dudit anticorps monoclonal, ou de fragments immunologiquement actifs de celui-ci, comme médicament pour le traitement et/ou la prévention de tumeurs cérébrales et de lésions cérébrales. Dans un mode de réalisation préféré de l'invention, l'anticorps monoclonal NILO1 ou ses fragments immunologiquement actifs sont humanisés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)